A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.


Updates from The Motley Fool

Latest updates on Dynavax Technologies from Fool.com.  The Fool has written over 100 articles on Dynavax Technologies.
5 Top Stocks for August

Don't let the summer heat stop you from buying shares of these five promising businesses.



Stock Performance

View Interactive DVAX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Dynavax Technologies.
Current Price: $18.65
Prev Close: $18.55
Open: $18.65
Bid: $18.65
Ask: $18.70
Day's Range: $18.30 - $18.75
52wk Range: $3.70 - $24.45
Volume: 271,768
Avg Vol 2,072,727
Market Cap: $1B
P/E (ttm): -9.66
EPS (ttm): ($1.92)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Dynavax Technologies.
CAPS Rating 4 out of 5
 
211 Outperform
13 Underperform
CAPS All Stars
 
35 Outperform
4 Underperform

How do you think Dynavax Technologies will perform against the market?



You pick for Dynavax Technologies is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Eddie Gray, CEO

76% Approve

Based on 8 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Dynavax Technologies.

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers